| Name | Title | Contact Details |
|---|
The future of medical image management is in the cloud. Unfortunately, the farther data travels the more lag time accrues. We call this latency. Radiologists and other physicians are accustomed to receiving images at rates of 50 frames per second. When traveling across the entire United States, it may drop to 10 frames per second - much too slow for acceptable patient care. NucleusHealth™ overcomes latency via our patent-pending streaming protocols, client-side rendering techniques, modern web browser technologies, and the computing horsepower of todays phones, laptops and desktops. Diagnostic quality images come to life on displays at blazing-fast speeds. Even large file types such as digital breast tomosynthesis can be displayed in seconds, not minutes. With that single achievement, NucleusHealth sets a new standard for performance, scalability, security, high availability and response times. Faster, more accurate care means better outcomes at a lower cost. The next generation of medical image management has been born.
Prince Agri Products, Inc. is a Quincy, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
Dental Health Alliance is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pathways Health Center For is a Sarnia, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.